Form 4: Chimerix CFO LaSpaluto Reports Share Disposal Following Merger with Jazz Pharmaceuticals

Michelle LaSpaluto, CFO of Chimerix, reports the disposal of shares and cancellation of stock options following the company's merger with Jazz Pharmaceuticals on April 21, 2025.

Summary

• Michelle LaSpaluto, CFO of Chimerix, filed a Form 4 on April 21, 2025, reporting changes in beneficial ownership of Chimerix stock.
• The filing details the disposal of 181,541 shares of common stock due to the merger between Chimerix and Jazz Pharmaceuticals, which became effective on April 21, 2025.
• The merger involved a tender offer where Jazz Pharmaceuticals acquired all outstanding shares of Chimerix for $8.55 per share.
• Outstanding restricted stock units (RSUs) were cancelled and converted into the right to receive a cash payment based on the offer price.
• In-the-money stock options were accelerated, vested, and converted into the right to receive a cash payment equal to the difference between the offer price and the exercise price.
• Out-of-the-money stock options were cancelled with no consideration.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports factual information about the completion of a merger. The impact on individual stakeholders (e.g., option holders) varies.

Positives

• Holders of in-the-money stock options received a cash payment for the difference between the offer price and the exercise price.

Negatives

• Holders of out-of-the-money stock options did not receive any consideration as their options were cancelled.
• Shareholders only received $8.55 per share.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Management Comments

• The foregoing descriptions in the footnotes to this Form 4 are qualified in their entirety by reference to the terms of the Merger Agreement.
• In the event of any conflict between the descriptions above and the terms set forth in the Merger Agreement, the terms set forth in the Merger Agreement shall control.

Industry Context

This announcement reflects a trend of pharmaceutical companies acquiring smaller firms to expand their product portfolios and pipelines. Jazz Pharmaceuticals' acquisition of Chimerix likely aims to leverage Chimerix's expertise and assets in a specific therapeutic area.

Comparison to Industry Standards

• Merger and acquisition (M&A) transactions in the pharmaceutical industry often involve a premium paid to the target company's shareholders.
• The $8.55 per share offer price represents the value Jazz Pharmaceuticals placed on Chimerix's assets and future potential.
• Comparable transactions can be analyzed to assess whether the offer price was fair relative to industry benchmarks.

Stakeholder Impact

• Shareholders received $8.55 per share.
• Holders of in-the-money options received a cash payment.
• Holders of out-of-the-money options received no consideration.
• Employees with RSUs received a cash payment.

Key Dates

Keywords

Chimerix, Jazz Pharmaceuticals, Merger, Form 4, LaSpaluto, Stock Options, RSUs, Beneficial Ownership, Tender Offer